Skip to main content

Austedo XR News

Teva Announces Austedo XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE) May 29, 2024 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. ...

Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo

New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD)...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Tardive Dyskinesia, Huntington's Disease

Austedo XR patient information at Drugs.com